MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 12-27-2025
BeyondSpring Market Cap 2011-2026 | BYSI
As of January 03, 2026 BeyondSpring has a market cap of $ 63.7 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap BeyondSpring
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56 M | 54.3 M | 37.9 M | 94 M | 389 M | 391 M | 408 M | 428 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 428 M | 37.9 M | 232 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 2.88 | -4.26 % | $ 223 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.32 | 7.79 % | $ 7.99 B |  Australia |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.9 | -4.5 % | $ 485 M | Britain |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 212.56 | -0.32 % | $ 5 B |  Danmark |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 10.81 | -4.21 % | $ 699 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.34 | 15.52 % | $ 1.98 M | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 96.62 | 1.49 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.21 | 5.66 % | $ 457 M |  Israel |
 |
CASI Pharmaceuticals
CASI
|
1.09 B | $ 0.86 | 0.86 % | $ 117 M | USA |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.33 | -1.68 % | $ 1.28 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 11.18 | -5.73 % | $ 736 M | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.41 | -2.08 % | $ 138 M | USA |
 |
Certara
CERT
|
1.98 B | $ 8.74 | -0.85 % | $ 1.4 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 563.06 | -0.86 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 27.12 | -0.15 % | $ 1.75 M | USA |
 |
Cellectis S.A.
CLLS
|
203 M | $ 4.82 | -0.41 % | $ 116 M | France |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.78 | 6.92 % | $ 17.5 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 91.64 | -0.32 % | $ 96.9 B | Britain |
 |
Cellectar Biosciences
CLRB
|
44.5 M | $ 3.41 | 15.59 % | $ 41.7 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |